Vasomotor Symptoms Market Report: Trends, Forecast and Competitive Analysis to 2030
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
In-depth interviews of the major players in this market
Detailed secondary research from competitors’ financial statements and published data
Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
In-depth interviews of the major players in this market
Detailed secondary research from competitors’ financial statements and published data
Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
1. EXECUTIVE SUMMARY
2. GLOBAL VASOMOTOR SYMPTOMS MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Vasomotor Symptoms Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Vasomotor Symptoms Market by Therapy Type
3.3.1: Estrogen
3.3.2: Progesterone
3.3.3: Combination
3.3.4: OTC Hormone
3.3.5: Anti-Depressants
3.3.6: Others
3.4: Global Vasomotor Symptoms Market by Distribution Channel
3.4.1: Hospital Pharmacy
3.4.2: Retail Pharmacy
3.4.3: Drug Stores
3.5: Global Vasomotor Symptoms Market by End Use
3.5.1: Hospitals and Clinics
3.5.2: Specialty Centers
3.5.3: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global Vasomotor Symptoms Market by Region
4.2: North American Vasomotor Symptoms Market
4.2.2: North American Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others
4.3: European Vasomotor Symptoms Market
4.3.1: European Vasomotor Symptoms Market by Therapy Type: Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants, and Others
4.3.2: European Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others
4.4: APAC Vasomotor Symptoms Market
4.4.1: APAC Vasomotor Symptoms Market by Therapy Type: Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants, and Others
4.4.2: APAC Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others
4.5: ROW Vasomotor Symptoms Market
4.5.1: ROW Vasomotor Symptoms Market by Therapy Type: Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants, and Others
4.5.2: ROW Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Vasomotor Symptoms Market by Therapy Type
6.1.2: Growth Opportunities for the Global Vasomotor Symptoms Market by Distribution Channel
6.1.3: Growth Opportunities for the Global Vasomotor Symptoms Market by End Use
6.1.4: Growth Opportunities for the Global Vasomotor Symptoms Market by Region
6.2: Emerging Trends in the Global Vasomotor Symptoms Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Vasomotor Symptoms Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Vasomotor Symptoms Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: Teva Pharmaceuticals
7.2: Merck
7.3: Mithra Pharmaceuticals
7.4: Procter and Gamble
7.5: TherapeuticsMD
7.6: Emcure Pharmaceuticals
7.7: Eli Lily and Company
7.8: Novartis
7.9: Novo Nordisk
7.10: Pfizer
2. GLOBAL VASOMOTOR SYMPTOMS MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Vasomotor Symptoms Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Vasomotor Symptoms Market by Therapy Type
3.3.1: Estrogen
3.3.2: Progesterone
3.3.3: Combination
3.3.4: OTC Hormone
3.3.5: Anti-Depressants
3.3.6: Others
3.4: Global Vasomotor Symptoms Market by Distribution Channel
3.4.1: Hospital Pharmacy
3.4.2: Retail Pharmacy
3.4.3: Drug Stores
3.5: Global Vasomotor Symptoms Market by End Use
3.5.1: Hospitals and Clinics
3.5.2: Specialty Centers
3.5.3: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global Vasomotor Symptoms Market by Region
4.2: North American Vasomotor Symptoms Market
4.2.2: North American Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others
4.3: European Vasomotor Symptoms Market
4.3.1: European Vasomotor Symptoms Market by Therapy Type: Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants, and Others
4.3.2: European Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others
4.4: APAC Vasomotor Symptoms Market
4.4.1: APAC Vasomotor Symptoms Market by Therapy Type: Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants, and Others
4.4.2: APAC Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others
4.5: ROW Vasomotor Symptoms Market
4.5.1: ROW Vasomotor Symptoms Market by Therapy Type: Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants, and Others
4.5.2: ROW Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Vasomotor Symptoms Market by Therapy Type
6.1.2: Growth Opportunities for the Global Vasomotor Symptoms Market by Distribution Channel
6.1.3: Growth Opportunities for the Global Vasomotor Symptoms Market by End Use
6.1.4: Growth Opportunities for the Global Vasomotor Symptoms Market by Region
6.2: Emerging Trends in the Global Vasomotor Symptoms Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Vasomotor Symptoms Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Vasomotor Symptoms Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: Teva Pharmaceuticals
7.2: Merck
7.3: Mithra Pharmaceuticals
7.4: Procter and Gamble
7.5: TherapeuticsMD
7.6: Emcure Pharmaceuticals
7.7: Eli Lily and Company
7.8: Novartis
7.9: Novo Nordisk
7.10: Pfizer
